View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Ambea AB: 1 director

A director at Ambea AB maiden bought 4,000 shares at 108.400SEK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

SamhAllsbyggnadsbolaget I Norden AB: 4 directors

Two Directors at SamhAllsbyggnadsbolaget I Norden AB bought 72,000 shares at between 4.720SEK and 5.212SEK. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...

ABGSC Services Research ... (+2)
  • ABGSC Services Research
  • Stefan Knutsson
ABGSC Services Research ... (+2)
  • ABGSC Services Research
  • Stefan Knutsson
Simen Mortensen
  • Simen Mortensen

More Q1 results and a proposed delisting

The Q1 reporting season is in full swing, with results from Catena, Entra, Pandox and Wihlborgs in the past week. In addition, Aurora Eiendom announced a proposal to delist from Euronext Growth Oslo. The weighted-average implied EBITDA yields on the stocks we cover are 5.00% for 2025e and 5.31% for 2026e.

ABGSC Services Research ... (+2)
  • ABGSC Services Research
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
Karl-Johan Bonnevier
  • Karl-Johan Bonnevier

Humana (Buy, TP: SEK52.00) - Growth agenda back in focus

The Q1 results were mixed, but with the financials now in good order, we see more of a growth focus ahead. We find management’s priorities logical, with our underlying forecast largely unchanged, but our 2025–2027e EPS cut by 6–2% on FX and non-cash items. We reiterate our BUY, but have trimmed our target price to SEK52 (53), focusing on Humana’s market opportunity, operating profile, financial outlook and valuation.

Simen Mortensen
  • Simen Mortensen

Signs of sector recovery, and more Q1 results

The markets were much quieter following the Easter break, with limited news; however, the names we cover saw their shares up 2.6% on average, with Atrium Ljungberg (7.1%), SBB (7.1%) and Pandox (4.8%) the top performers. JM released its Q1 results and we reiterated our BUY, believing it has passed the earnings trough, while we reiterated our HOLDs on Corem and Fabege following their quarterly reports. The weighted-average implied EBITDA yields on the stocks we cover are 5.04% for 2025e and 5.34%...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson

BioArctic AB: 3 directors

Three Directors at BioArctic AB bought 3,120 shares at between 163.200SEK and 164.700SEK. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch